SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a ...

A key ocean current in the North Atlantic Ocean is weakening to the point of total collapse due to climate change, a new study warns. Scientists say the North Atlantic Subpolar Gyre – a massive system ...

Gyre Therapeutics' stock is volatile - I'm upholding my "Hold" rating due to uncertain long-term prospects and potential dilution from future funding needs. The company's products include Etuary, and ...